Etoposide phosphate

Etoposide phosphate (BMY-40481) is a potent anti-cancer chemotherapy agent and a selective topoisomerase II inhibitor to prevent re-ligation of DNA strands. Etoposide phosphate is the phosphate ester prodrug of etoposide and is considered as active equivalent to Etoposide. Etoposide phosphate induces cell cycle arrest, apoptosis, and autophagy^[1][2]. In Vitro: Etoposide phosphate is a water-soluble derivative and probable prodrug of etoposide characterized by the presence of a phosphate group in position 4' of the E ring of the etoposide molecule^[1].
Etoposide phosphate (0-1 μM; 72 hours) inhibits HCT116 FBXW^+/+, FBXW^-/- and p53^-/- as a dose-dependent manner, exhibits IC₅₀ values of 0.945 μM; 0.375 μM; and 1.437 μM, respectively^[2].
Etoposide phosphate (25 μM; 6 hours) delays p53 recover in FBXW7-deficient cells. In addition, FBXW7 expression is disappeared in FBXW7^-/- cells^[2].
In Vivo: Etoposide phosphate (intravenous injection; 50, 100, or 150 mg/kg; single dose) has clinical symptomology of progressive ataxia, impaired righting reflex, and splaying and paresis of fore- and hindlimbs at day 8 in female CD-1 mice^[3].